Boston Biomedical to Highlight Data Examining Novel Investigational Cancer Stem Cell Pathway Inhibitors BBI608 and BBI503 in Multiple Cancer Types at ASCO 2015

CAMBRIDGE, Mass. May 13, 2015 – Boston Biomedical, an industry leader in the development of novel compounds designed to target cancer stem cell (CSC) pathways, will present clinical data on the investigational compounds BBI608 and BBI503 in multiple tumor types at the 2015 American Society of Clinical Oncology annual meeting, held from May 29 to June 2, 2015, in Chicago, IL.

Data to be highlighted at the meeting show the potential of BBI608—an orally-administered investigational agent that targets STAT3, leading to inhibition of the critical genes for maintaining cancer stemness—for anti-cancer activity when used in combination with other chemotherapeutics across varying advanced cancers, including gastric and colorectal. The study protocol from the BRIGHTER study, the Phase 3 clinical trial currently underway to investigate cancer stem cell pathway inhibitors, will also be showcased.

Additional data featuring BBI503—an orally-administered investigational agent designed to inhibit Nanog and other cancer stem cell pathways by targeting kinases—showed encouraging early signs of anti-cancer activity for patients with advanced colorectal cancer.

Also, findings from a publication-only abstract will be available:

- Abstract #e15089: A phase I study of BBI608, a cancer stemness inhibitor, administered with paclitaxel (PTX) as combination therapy (Rx) for pretreated unresectable or recurrent gastric cancer
  - Kohei Shitara, MD, National Cancer Center Hospital East

Poster presentations include:

- **Monday, June 1 from 8:00 a.m. – 11:30 a.m. (Gastrointestinal (Colorectal) Cancer), S Hall A**
  - Abstract #3615, Poster #108: Phase 1 extension study of BBI503, a first-in-class cancer stemness kinase inhibitor, in patients with advanced colorectal cancer
    - Derek J. Jonker, MD, FRCPC, The Ottawa Hospital Cancer Centre
  - Abstract #3616, Poster #109: A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC)
    - Joleen Marie Hubbard, MD, Mayo Clinic
  - Abstract #3617, Poster #110: A phase Ib/II study of cancer stem cell inhibitor BBI608 administered with panitumumab in KRAS wild-type (wt) patients (pts) with metastatic colorectal cancer (mCRC) following progression on anti-EGFR therapy
    - Kristen Keon Ciombor, MD, Ohio State University Wexner Medical Center
Monday, June 1 from 8:00 a.m. – 11:30 a.m. (Gastrointestinal (Noncolorectal) Cancer), S Hall A

- Abstract #4069, Poster #179: A phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma
  - Carlos Becerra, MD, Texas Oncology-Baylor Sammons Cancer Center
- Abstract #TPS4139, Poster #247a: The BRIGHTER trial: A phase III randomized double-blind study of BBI608 + weekly paclitaxel versus placebo (PBO) + weekly paclitaxel in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma
  - Manish A. Shah, MD, Weill Cornell Medical College

“We look forward to sharing these encouraging findings of first-in-class compounds BBI608 and BBI503 at this year’s ASCO annual meeting,” said Chiang J. Li, M.D. FACP, the President, CEO and Chief Medical Officer of Boston Biomedical, and the Head of Global Oncology for Sumitomo Dainippon Pharma Group. “We are pleased to see the progress to date and are planning for the continued evaluation of these compounds that may ultimately improve patient care and shift the treatment continuum.”

About Boston Biomedical

Boston Biomedical, Inc. (Founder, President, CEO and CMO: Chiang J. Li, M.D. FACP) was founded in November, 2006 and is wholly owned by Sumitomo Dainippon Pharma Co., Ltd. Boston Biomedical’s mission is to develop the next generation of cancer therapeutics by creating drugs designed to target cancer stem cell pathways. Boston Biomedical’s innovation in drug discovery has received a number of recognitions and awards in the United States, including the Frost & Sullivan 2010 North American Drug Discovery Technology Innovation of the Year Award, the National Cancer Institute (NCI) cancer stem cell initiative grant award in 2010, and the 2011 Biotech Pioneer Award at the Alexandria Oncology Summit. The company also received the “Company To Watch” award in the 10th Annual Team Massachusetts Economic Impact Awards in 2013. Boston Biomedical is headquartered in Cambridge, Massachusetts, USA.

Additional information about the company and its product pipeline can be found at www.bostonbiomedical.com.

Disclaimer Regarding Forward-Looking Statements

The forward-looking statements in this document are based on management’s assumptions and beliefs in light of information presently available, and involve both known and unknown risks and uncertainties. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice.

Contact: Boston Biomedical Phone: 617-674-6800